831 related articles for article (PubMed ID: 19805701)
1. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.
Hulse GK; Morris N; Arnold-Reed D; Tait RJ
Arch Gen Psychiatry; 2009 Oct; 66(10):1108-15. PubMed ID: 19805701
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone.
Hulse GK; Ngo HT; Tait RJ
Biol Psychiatry; 2010 Aug; 68(3):296-302. PubMed ID: 20537615
[TBL] [Abstract][Full Text] [Related]
3. Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants.
Hulse GK; Arnold-Reed DE; O'Neil G; Chan CT; Hansson R; O'Neil P
Addict Biol; 2004 Mar; 9(1):59-65. PubMed ID: 15203440
[TBL] [Abstract][Full Text] [Related]
4. Blood naltrexone levels over time following naltrexone implant.
Ngo HT; Arnold-Reed DE; Hansson RC; Tait RJ; Hulse GK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):23-8. PubMed ID: 17651881
[TBL] [Abstract][Full Text] [Related]
5. Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance or naltrexone implantation.
Ngo HT; Tait RJ; Hulse GK
Arch Gen Psychiatry; 2008 Apr; 65(4):457-65. PubMed ID: 18391134
[TBL] [Abstract][Full Text] [Related]
6. Achieving long-term continuous blood naltrexone and 6-beta-naltrexol coverage following sequential naltrexone implants.
Hulse GK; Arnold-Reed DE; O'Neil G; Chan CT; Hansson RC
Addict Biol; 2004 Mar; 9(1):67-72. PubMed ID: 15203441
[TBL] [Abstract][Full Text] [Related]
7. Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels.
Foster J; Brewer C; Steele T
Addict Biol; 2003 Jun; 8(2):211-7. PubMed ID: 12850780
[TBL] [Abstract][Full Text] [Related]
8. A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in 'high-risk' adolescent heroin users.
Hulse GK; Tait RJ
Addict Biol; 2003 Sep; 8(3):337-42. PubMed ID: 13129836
[TBL] [Abstract][Full Text] [Related]
9. Mental health outcomes following naltrexone implant treatment for heroin-dependence.
Ngo HT; Tait RJ; Arnold-Reed DE; Hulse GK
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):605-12. PubMed ID: 17229510
[TBL] [Abstract][Full Text] [Related]
10. Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia.
Krupitsky EM; Zvartau EE; Masalov DV; Tsoy MV; Burakov AM; Egorova VY; Didenko TY; Romanova TN; Ivanova EB; Bespalov AY; Verbitskaya EV; Neznanov NG; Grinenko AY; O'Brien CP; Woody GE
J Subst Abuse Treat; 2006 Dec; 31(4):319-28. PubMed ID: 17084785
[TBL] [Abstract][Full Text] [Related]
11. Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine.
Reece AS
J Subst Abuse Treat; 2009 Oct; 37(3):256-65. PubMed ID: 19394789
[TBL] [Abstract][Full Text] [Related]
12. A randomised, controlled trial of low dose naltrexone for the treatment of opioid dependence.
Rea F; Bell JR; Young MR; Mattick RP
Drug Alcohol Depend; 2004 Jul; 75(1):79-88. PubMed ID: 15225891
[TBL] [Abstract][Full Text] [Related]
13. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.
Dunbar JL; Turncliff RZ; Dong Q; Silverman BL; Ehrich EW; Lasseter KC
Alcohol Clin Exp Res; 2006 Mar; 30(3):480-90. PubMed ID: 16499489
[TBL] [Abstract][Full Text] [Related]
14. A comparison of mental health hospital admissions in a cohort of heroin users prior to and after rapid opiate detoxification and oral naltrexone maintenance.
Arnold-Reed DE; O'Neil P; Holman CD; Bulsara MK; Rodiguez C; Gawthorne G; Tait RJ; Hulse GK
Am J Drug Alcohol Abuse; 2007; 33(5):655-64. PubMed ID: 17891658
[TBL] [Abstract][Full Text] [Related]
15. Blood morphine levels in naltrexone-exposed compared to non-naltrexone-exposed fatal heroin overdoses.
Arnold-Reed DE; Hulse GK; Hansson RC; Murray SD; O'Neil G; Basso MR; Holman CD
Addict Biol; 2003 Sep; 8(3):343-50. PubMed ID: 13129837
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence.
Krupitsky E; Zvartau E; Blokhina E; Verbitskaya E; Wahlgren V; Tsoy-Podosenin M; Bushara N; Burakov A; Masalov D; Romanova T; Tyurina A; Palatkin V; Slavina T; Pecoraro A; Woody GE
Arch Gen Psychiatry; 2012 Sep; 69(9):973-81. PubMed ID: 22945623
[TBL] [Abstract][Full Text] [Related]
17. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment.
Tait RJ; Ngo HT; Hulse GK
J Subst Abuse Treat; 2008 Sep; 35(2):116-24. PubMed ID: 17931824
[TBL] [Abstract][Full Text] [Related]
18. Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants.
Hulse GK; Tait RJ; Comer SD; Sullivan MA; Jacobs IG; Arnold-Reed D
Drug Alcohol Depend; 2005 Sep; 79(3):351-7. PubMed ID: 15899557
[TBL] [Abstract][Full Text] [Related]
19. Hospital psychiatric comorbidity and its role in heroin dependence treatment outcomes using naltrexone implant or methadone maintenance.
Ngo HT; Tait RJ; Hulse GK
J Psychopharmacol; 2011 Jun; 25(6):774-82. PubMed ID: 20360157
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial.
Galloway GP; Koch M; Cello R; Smith DE
BMC Psychiatry; 2005 Apr; 5():18. PubMed ID: 15804355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
